Literature DB >> 1761081

Relation between plasma concentration and clinical efficacy after sublingual single dose apomorphine in Parkinson's disease.

F Durif1, E Jeanneau, F Serre-Debeauvais, D Deffond, A Eschalier, M Tournilhac.   

Abstract

Five patients with Parkinson's disease were given a single sublingual dose of apomorphine in 3 mg tablets (2 patients received 18 mg and 3 patients took 39 mg). The therapeutic effect appeared within 33.0 min and lasted 137 min. There was a significant correlation between peak concentration, area under the curve, dose (mg/kg) and the duration of the therapeutic effect.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1761081     DOI： 10.1007/BF00626377

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  8 in total

1.  Efficacy of sublingual apomorphine in Parkinson's disease.

Authors:  F Durif; D Deffond; M Tournilhac
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-12       Impact factor: 10.154

2.  Sublingual apomorphine and Parkinson's disease.

Authors:  A J Lees; J L Montastruc; N Turjanski; O Rascol; B Kleedorfer; H Peyro Saint-Paul; G M Stern; A Rascol
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

3.  Subcutaneous apomorphine in parkinsonian on-off oscillations.

Authors:  C M Stibe; A J Lees; P A Kempster; G M Stern
Journal:  Lancet       Date:  1988-02-20       Impact factor: 79.321

4.  Subcutaneous apomorphine in Parkinson's disease.

Authors:  W Poewe; B Kleedorfer; F Gerstenbrand; W Oertel
Journal:  Lancet       Date:  1988-04-23       Impact factor: 79.321

5.  Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.

Authors:  G C Cotzias; P S Papavasiliou; E S Tolosa; J S Mendez; M Bell-Midura
Journal:  N Engl J Med       Date:  1976-03-11       Impact factor: 91.245

6.  Determination of apomorphine in rat plasma and brain by high-performance liquid chromatography with electrochemical detection.

Authors:  G Bianchi; M Landi
Journal:  J Chromatogr       Date:  1985-02-27

7.  Onset and end-of-dose levodopa-induced dyskinesias. Possible treatment by increasing the daily doses of levodopa.

Authors:  F Lhermitte; Y Agid; J L Signoret
Journal:  Arch Neurol       Date:  1978-05

8.  [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].

Authors:  P Pollak; A S Champay; J M Gaio; M Hommel; A L Benabid; J Perret
Journal:  Rev Neurol (Paris)       Date:  1990       Impact factor: 2.607
  8 in total
  2 in total

Review 1.  Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease.

Authors:  C Neef; T van Laar
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 2.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.